Therapeutic Asset Ratings
19,639 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Cyclophosphamide
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
Peking University People's Hospital
P2
BB
(68)
Cyclophosphamide
Estrogen-Receptor Positive Breast Cancer
UNC Lineberger Comprehensive Cancer Center
P2
BB
(68)
Cyclophosphamide
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma
University of Washington
P2
BB
(68)
Cyclophosphamide
Indolent B-Cell Non-Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P2
BB
(68)
Cyclophosphamide
Fallopian Tube Carcinoma
Mayo Clinic
P2
BB
(68)
Cyclophosphamide
Sarcoma
Essen Biotech
P2
BB
(68)
Cyclophosphamide
Small Intestine Cancer
National Cancer Institute (NCI)
P2
BB
(68)
CYCLOSPORIN A
Anaplastic Large Cell Lymphoma
Fred Hutchinson Cancer Center
P2
BB
(68)
Decitabine
Myelodysplastic/Myeloproliferative Neoplasm
University of Washington
P2
BB
(68)
DEXAMETHASONE
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
OHSU Knight Cancer Institute
P2
BB
(68)
DEXAMETHASONE
Hematopoietic and Lymphoid Cell Neoplasm
Therapeutic Advances in Childhood Leukemia Consortium
P2
BB
(68)
DEXAMETHASONE
Nodal Marginal Zone B-Cell Lymphoma
Izidore Lossos, MD
P2
BB
(68)
DEXAMETHASONE
Splenic Marginal Zone Lymphoma
Izidore Lossos, MD
P2
BB
(68)
DEXAMETHASONE
Waldenstrom Macroglobulinemia
Christian Buske
P2
BB
(68)
Eloxatin
Adenocarcinoma
University of Chicago
P2
BB
(68)
Eloxatin
Soft Tissue Sarcoma
OHSU Knight Cancer Institute
P2
BB
(68)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Ureter Neoplasm
Eli Lilly and Company
P2
BB
(68)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Urinary Bladder Neoplasm
Eli Lilly and Company
P2
BB
(68)
Enzalutamide
Breast Carcinoma
Nuvation Bio Inc.
P2
BB
(68)
Enzalutamide
Triple-Negative Breast Carcinoma
Nuvation Bio Inc.
P2
BB
(68)
Epirubicin
Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Seda S. Tolu
P2
BB
(68)
Epirubicin
Recurrent Fallopian Tube Carcinoma
Roswell Park Cancer Institute
P2
BB
(68)
ETOPOSIDE
Acute Myeloid Leukemia With Multilineage Dysplasia
Institut de Recherches Internationales Servier
P2
BB
(68)
ETOPOSIDE
Neuroendocrine Carcinoma
National Cancer Institute (NCI)
P2
BB
(68)
ETOPOSIDE
Plasmablastic Lymphoma
National Cancer Institute (NCI)
P2
BB
(68)
Showing 351 to 375 of 19,639 assets
Previous
Page 15 of 786
Next